Latest research on Humalog

Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996.

Humalog dosage

For ITT, mice fasted for 4 h were challenged with an i.p. injection of insulin lispro (Humalog, Lilly) at a dose of 0.75 (for chow-fed mice) or 1.5 U kg−1 (for HFD-fed mice). [source, 2015]
Humalog was stopped completely and the dose of glargine was gradually reduced to four units once a day. [source, 2015]
Kazda et al23 found that, among patients who started insulin therapy with either HM50 or Humalog, BMI gain was significantly less in the former (0.6±1.1 vs 0.9±1.5, p<0.005), despite patients taking a higher daily dose of insulin in the HM50 group (0.59±0.3 U/kg vs 0.50±0.23 U/kg, p<0.005). [source, 2014]
Insulin lispro (Humalog, Lilly, Indianapolis, IN, USA) was administered in a 1:10 dilution at an initial basal rate of 0.016 U/kg/hr, according to the most recent dose of intravenous infusion. [source, 2013]
The average insulin dose remained unchanged for each patient throughout the duration of the study when compared with pretreatment/baseline even though the specific insulin formulation varied (Lantus long-acting insulin with multiple daily injections of Humalog, Humulin injectable or pump, or Novolog injectable). [source, 2011]
One simulation study comparing the Humalog Pen to the FlexPen® demonstrated that patients scored the FlexPen® significantly higher in overall ease of use, including ease of dose setting (P < 0.001), ease in pressing the release button (P < 0.01), and simplicity (P < 0.01); the higher rating for the FlexPen® was consistent for patients with both visual and manual dexterity impairments as well. [source, 2010]
Similarly, another study comparing the FlexPen® to the Humalog pen device found that 74% of patients preferred the FlexPen® for overall ease of use, including the following parameters: ease of reading the dose scale, ease of feeling the click for each unit increment, ease of depressing the injection button, ease of turning the dose selector, and ease of determining that push button was completely depressed. [source, 2010]
When pen devices have been compared head-to-head (FlexPen vs. Humalog Pen vs. syringe), significant improvements in patient preferences have been found in favor of the devices which improve the readability of the dose scale and user confidence [28,38]. [source, 2007]